0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      β‐arrestin2 recruitment at the β2 adrenergic receptor: A luciferase complementation assay adapted for undergraduate training in pharmacology

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In the context of pharmacology teaching, hands‐on activities constitute an essential complement to theoretical lectures. Frequently, these activities consist in exposing fresh animal tissues or even living animals to selected drugs and qualitatively or quantitatively evaluating functional responses. However, technological advancements in pharmacological research and the growing concerns for animal experimentation support the need for innovative and flexible in vitro assays adapted for teaching purposes. We herein report the implementation of a luciferase complementation assay (LCA) enabling to dynamically monitor β‐arrestin2 recruitment at the β 2 adrenergic receptor in the framework of pharmacological training at the faculty of Pharmacy and Biomedical Sciences. The assay allowed students to quantitatively characterize the competitive antagonism of propranolol, and to calculate pEC 50, pK B, and pA 2 values after a guided data analysis session. Moreover, the newly implemented workshop delivered highly reproducible results and were generally appreciated by students. As such, we report that the luciferase complementation‐based assay proved to be a straightforward, robust, and cost‐effective alternative to experiments performed on animal tissues, constituting a useful and flexible tool to enhance and update current hands‐on training in the context of pharmacological teaching.

          Abstract

          The novel, animal‐free pharmacology workshop implemented at our faculty, combining in vitro experiments and data analysis sessions. It consists in a luciferase complementation assay (LCA) enabling to dynamically monitor β‐arrestin2 recruitment at the β2 adrenergic receptor. It allows students to characterize the competitive antagonism of propranolol by calculating pEC50, pKB, and pA2 values.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Principles of early drug discovery.

          Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion. The idea for a target can come from a variety of sources including academic and clinical research and from the commercial sector. It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery programme. Once a target has been chosen, the pharmaceutical industry and more recently some academic centres have streamlined a number of early processes to identify molecules which possess suitable characteristics to make acceptable drugs. This review will look at key preclinical stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development. © 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors

            The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (http://www.guidetopharmacology.org/), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.14748. G protein‐coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

              Abstract The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, www.guidetopharmacology.org) and its precursor IUPHAR-DB, have captured expert-curated interactions between targets and ligands from selected papers in pharmacology and drug discovery since 2003. This resource continues to be developed in conjunction with the International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Pharmacological Society (BPS). As previously described, our unique model of content selection and quality control is based on 96 target-class subcommittees comprising 512 scientists collaborating with in-house curators. This update describes content expansion, new features and interoperability improvements introduced in the 10 releases since August 2015. Our relationship matrix now describes ∼9000 ligands, ∼15 000 binding constants, ∼6000 papers and ∼1700 human proteins. As an important addition, we also introduce our newly funded project for the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb, www.guidetoimmunopharmacology.org). This has been ‘forked’ from the well-established GtoPdb data model and expanded into new types of data related to the immune system and inflammatory processes. This includes new ligands, targets, pathways, cell types and diseases for which we are recruiting new IUPHAR expert committees. Designed as an immunopharmacological gateway, it also has an emphasis on potential therapeutic interventions.
                Bookmark

                Author and article information

                Contributors
                emmanuel.hermans@uclouvain.be
                Journal
                Pharmacol Res Perspect
                Pharmacol Res Perspect
                10.1002/(ISSN)2052-1707
                PRP2
                Pharmacology Research & Perspectives
                John Wiley and Sons Inc. (Hoboken )
                2052-1707
                28 January 2021
                February 2021
                : 9
                : 1 ( doiID: 10.1002/prp2.v9.1 )
                : e00706
                Affiliations
                [ 1 ] Neuropharmacology Laboratory Institute of Neuroscience UCLouvain Brussels Belgium
                [ 2 ] Faculty of Pharmacy and Biomedical Sciences UCLouvain Brussels Belgium
                [ 3 ] Laboratory of Molecular Pharmacology GIGA‐Molecular Biology of Disease ULiège Liège Belgium
                Author notes
                [*] [* ] Correspondence

                Emmanuel Hermans, Avenue Hippocrate 54/B1.54.10, 1200 Woluwe‐Saint‐Lambert, UCLouvain, Brussels, Belgium.

                Author information
                https://orcid.org/0000-0002-4332-9055
                https://orcid.org/0000-0001-9027-2525
                https://orcid.org/0000-0001-8915-795X
                https://orcid.org/0000-0001-7063-7590
                https://orcid.org/0000-0002-8589-3279
                Article
                PRP2706
                10.1002/prp2.706
                7842874
                33508174
                50e820be-1574-46cb-8567-30196b1bbf07
                © 2021 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 23 October 2020
                : 25 November 2020
                : 30 November 2020
                Page count
                Figures: 6, Tables: 0, Pages: 10, Words: 10162
                Funding
                Funded by: Faculté de Pharmacie et Sciences Biomédicales, UCLouvain, Fonds De La Recherche Scientifique ‐ FNRS , open-funder-registry 10.13039/501100002661;
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                February 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.7 mode:remove_FC converted:28.01.2021

                arrestin,g protein‐coupled receptor,luciferase,pa2,teaching,undergraduate,β2 adrenergic receptor

                Comments

                Comment on this article